Cardiovascular events in patients with Fabry disease: Natural history data from the Fabry Registry

Journal of the American College of Cardiology

Volumn 57, Issue 9, 2011, Pages 1093-1099

  Patel, Manesh R ^a   Cecchi, Franco ^b   Cizmarik, Marta ^c   Kantola, Ilkka ^d   Linhart, Ales ^e   Nicholls, Kathy ^f   Strotmann, Jrg ^g   Tallaj, Jose ^h   Tran, Thi Chien ⁱ   West, Michael L ^j   Beitner Johnson, Dana ^c   Abiose, Ademola ^k  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c GENZYME CORPORATION   (United States)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g 1 Medizinische Klinik   (Germany)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j DALHOUSIE UNIVERSITY   (Canada)

^k UNIVERSITY OF IOWA   (United States)

more..

Author keywords

cardiomyopathyy; Fabry disease; hypertension; left ventricular hypertrophy; lysosomal storage diseases

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FABRY DISEASE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RISK FACTOR;

CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; WORLD HEALTH;

EID: 79951983786     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.11.018     Document Type: Article

References (33)

1. R.J. Desnick, Y.A. Ioannou, and C.M. Eng Alpha-galactosidase A deficiency: Fabry disease C. Scriver, A. Beaudet, W. Sly, D. Valle, The Metabolic Bases of Inherited Disease 8th edition 2001 McGraw-Hill New York, NY 3733 3774
2. M.H. Branton, R. Schiffmann, and S.G. Sabnis Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course Medicine (Baltimore) 81 2002 122 138 (Pubitemid 34218568)
3. A. Mehta, R. Ricci, and U. Widmer Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Eur J Clin Invest 34 2004 236 242 (Pubitemid 38406640)
4. R. Schiffmann, D.G. Warnock, and M. Banikazemi Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy Nephrol Dial Transplant 24 2009 2102 2111
5. K. Sims, J. Politei, M. Banikazemi, and P. Lee Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry Stroke 40 2009 788 794
6. W.R. Wilcox, J.P. Oliveira, and R.J. Hopkin Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry Mol Genet Metab 93 2008 112 128
7. B. Pierre-Louis, A. Kumar, and W.H. Frishman Fabry disease: cardiac manifestations and therapeutic options Cardiol Rev 17 2009 31 35
8. F. Weidemann, A. Linhart, L. Monserrat, and J. Strotmann Cardiac challenges in patients with Fabry disease Int J Cardiol 141 2010 3 10
9. F. Weidemann, J.M. Strotmann, and M. Niemann Heart valve involvement in Fabry cardiomyopathy Ultrasound Med Biol 35 2009 730 735
10. J.S. Shah, D.A. Hughes, and B. Sachdev Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease Am J Cardiol 96 2005 842 846 (Pubitemid 41319722)
11. R.J. Hopkin, J. Bissler, and M. Banikazemi Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry Pediatr Res 64 2008 550 555
12. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
13. K.E. Muller, and B.A. Fetterman Section 11.5.5., selecting the best model Regression and ANOVA: An Integrated Approach Using SAS Software 2002 SAS Institute, Inc Cary, North Carolina 231
14. W.B. Dobyns, A. Filauro, and B.N. Tomson Inheritance of most X-linked traits is not dominant or recessive, just X-linked Am J Med Genet A 129A 2004 136 143 (Pubitemid 39121279)
15. F. Weidemann, F. Breunig, and M. Beer The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease Eur Heart J 26 2005 1221 1227 (Pubitemid 40863129)
16. C.M. Eng, D.P. Germain, and M. Banikazemi Fabry disease: guidelines for the evaluation and management of multi-organ system involvement Genet Med 8 2006 539 548 (Pubitemid 44402030)
17. A.V. Chobanian, G.L. Bakris, and H.R. Black Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252 (Pubitemid 37553153)
18. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
19. C. Kampmann, A. Linhart, R.B. Devereux, and R. Schiffmann Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis Clin Ther 31 2009 1966 1976
20. J.C. Moon, M. Sheppard, E. Reed, P. Lee, P.M. Elliott, and D.J. Pennell The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease J Cardiovasc Magn Reson 8 2006 479 482
21. O. Suzuki, and M. Abe An autopsy case of Fabry's disease with cardiac manifestations J Clin Exp Hematop 49 2009 121 123
22. L.C. Amado, and J.A. Lima Myocardial scar as arrhythmia risk in patients with hypertrophic cardiomyopathy Curr Opin Cardiol 25 2010 276 281
23. S. Pujadas, R. Vidal-Perez, and A. Hidalgo Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study Eur J Radiol 75 2010 e88 e91
24. V.O. Puntmann, Y.G. Yap, W. McKenna, and A.J. Camm Significance of maximal and regional left ventricular wall thickness in association with arrhythmic events in patients with hypertrophic cardiomyopathy Circ J 74 2010 531 537
25. M. Beer, F. Weidemann, and F. Breunig Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy Am J Cardiol 97 2006 1515 1518
26. F. Breunig, F. Weidemann, J. Strotmann, A. Knoll, and C. Wanner Clinical benefit of enzyme replacement therapy in Fabry disease Kidney Int 69 2006 1216 1221
27. D.A. Hughes, P.M. Elliott, and J. Shah Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa Heart 94 2008 153 158 (Pubitemid 351211719)
28. F. Weidemann, F. Breunig, and M. Beer Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study Circulation 108 2003 1299 1301 (Pubitemid 37174405)
29. F. Weidemann, M. Niemann, and F. Breunig Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment Circulation 119 2009 524 529
30. M. Banikazemi, J. Bultas, and S. Waldek Agalsidase-beta therapy for advanced Fabry disease: a randomized trial Ann Intern Med 146 2007 77 86 (Pubitemid 351640010)
31. D.P. Germain, S. Waldek, and M. Banikazemi Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease J Am Soc Nephrol 18 2007 1547 1557 (Pubitemid 46717522)
32. M. West, K. Nicholls, and A. Mehta Agalsidase alfa and kidney dysfunction in Fabry disease J Am Soc Nephrol 20 2009 1132 1139
33. A. Ortiz, J.P. Oliveira, C. Wanner, B.M. Brenner, S. Waldek, and D.G. Warnock Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults Nat Clin Pract Nephrol 4 2008 327 336 (Pubitemid 351769331)